Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.7334
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.286
- MktCap 992485244666.0
- FreeCF/Share 10.0576
- PFCF 110.0231
- PE 53.9306
- Debt/Assets 0.3698
- DivYield 0.0054
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
"Disappointment Overall" for LLY Earnings, ABNB Shows Travel Weakness
Published: August 07, 2025 by: Schwab Network
Sentiment: Negative
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
Read More
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Published: August 07, 2025 by: Reuters
Sentiment: Negative
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
There Is Only 1 GLP-1 Stock to Buy In 2025
Published: August 06, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Key Points in This Article: Ozempic's introduction shifted obesity treatment from lifestyle to pharmacological solutions, using GLP-1 drugs to regulate appetite and glucose.
Read More
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Published: August 05, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Read More
Trim Your AI Stocks And Buy Eli Lilly
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
AI and semiconductor stocks are too expensive right now. Don't buy them now, trim your high-tech positions, and buy healthcare stocks like Eli Lilly and Company. LLY is a hyper-growth-at-a-reasonable-price play. A 30% 12-month return is reasonable to anticipate. It is not too early to buy healthcare stocks; it will just require patience. I'd rather leave the party first and miss the traffic than move with the crowd.
Read More
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Published: July 31, 2025 by: Benzinga
Sentiment: Positive
Eli Lilly and Co. LLY released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.
Read More
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 …
Read More
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Read More
Lilly set for strong quarter after Novo profit warning
Published: July 29, 2025 by: Reuters
Sentiment: Positive
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.
Read More
The Big 3: OKTA, LLY, ADSK
Published: July 25, 2025 by: Schwab Network
Sentiment: Positive
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technical breakout," and Autodesk's (ADSK) path to reclaim its 52-week high.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Published: July 24, 2025 by: Business Wire
Sentiment: Neutral
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to $856 million. The updated release reads: GATE BIOSCIENCE ENTERS INTO A COLLABORATION AND LICENSE AGREE.
Read More
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
Published: July 24, 2025 by: Benzinga
Sentiment: Positive
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials
Read More
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
Published: July 24, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.
Read More
Calls of the Day: Eli Lilly and Materion
Published: July 18, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Read More
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000